These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34315517)

  • 1. A spatial-epidemiological dataset of subjects infected by SARS-CoV-2 during the first wave of the pandemic in Mashhad, second-most populous city in Iran.
    MohammadEbrahimi S; Mohammadi A; Bergquist R; Akbarian M; Arian M; Pishgar E; Kiani B
    BMC Res Notes; 2021 Jul; 14(1):292. PubMed ID: 34315517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological characteristics and initial spatiotemporal visualisation of COVID-19 in a major city in the Middle East.
    MohammadEbrahimi S; Mohammadi A; Bergquist R; Dolatkhah F; Olia M; Tavakolian A; Pishgar E; Kiani B
    BMC Public Health; 2021 Jul; 21(1):1373. PubMed ID: 34247616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year spatiotemporal database of Emergency Medical Service (EMS) calls in Mashhad, Iran: data on 224,355 EMS calls.
    Hashtarkhani S; Kiani B; Mohammadi A; MohammadEbrahimi S; Eslami S; Tara M; Matthews SA
    BMC Res Notes; 2022 Jan; 15(1):22. PubMed ID: 35078516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial modeling, risk mapping, change detection, and outbreak trend analysis of coronavirus (COVID-19) in Iran (days between February 19 and June 14, 2020).
    Pourghasemi HR; Pouyan S; Heidari B; Farajzadeh Z; Fallah Shamsi SR; Babaei S; Khosravi R; Etemadi M; Ghanbarian G; Farhadi A; Safaeian R; Heidari Z; Tarazkar MH; Tiefenbacher JP; Azmi A; Sadeghian F
    Int J Infect Dis; 2020 Sep; 98():90-108. PubMed ID: 32574693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demographics, clinical characteristics, and outcomes of 27,256 hospitalized COVID-19 patients in Kermanshah Province, Iran: a retrospective one-year cohort study.
    Hesni E; Sayad B; Khosravi Shadmani F; Najafi F; Khodarahmi R; Rahimi Z; Bozorgomid A; Sayad N
    BMC Infect Dis; 2022 Mar; 22(1):319. PubMed ID: 35361161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatial and temporal analysis of the COVID-19 incidence pattern in Iran.
    Hazbavi Z; Mostfazadeh R; Alaei N; Azizi E
    Environ Sci Pollut Res Int; 2021 Mar; 28(11):13605-13615. PubMed ID: 33188632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excess deaths during the COVID-19 pandemic in Iran.
    Ahmadi Gohari M; Chegeni M; Haghdoost AA; Mirzaee F; White L; Kostoulas P; Mirzazadeh A; Karamouzian M; Jahani Y; Sharifi H
    Infect Dis (Lond); 2022 Dec; 54(12):909-917. PubMed ID: 36121798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study.
    Khan M; Khan H; Khan S; Nawaz M
    J Med Microbiol; 2020 Aug; 69(8):1114-1123. PubMed ID: 32783802
    [No Abstract]   [Full Text] [Related]  

  • 14. Epidemic size, trend and spatiotemporal mapping of SARS-CoV-2 using geographical information system in Alborz Province, Iran.
    Kabir K; Taherinia A; Ashourloo D; Khosravi A; Karim H; Salehi Shahrabi H; Hedayat Yaghoobi M; Soleimani A; Siami Z; Noorisepehr M; Tajbakhsh R; Maghsoudi MR; Lak M; Mardi P; Nouri B; Mohammadzadeh M; Azimzadeh M; Bakhtiyari M
    BMC Infect Dis; 2021 Nov; 21(1):1185. PubMed ID: 34823478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends and forecasting of COVID-19 hospitalisations and deaths in Scotland using a national real-time patient-level data platform: a statistical modelling study.
    Simpson CR; Robertson C; Vasileiou E; Moore E; McCowan C; Agrawal U; Stagg HR; Docherty A; Mulholland R; Murray JLK; Ritchie LD; McMenamin J; Sheikh A
    Lancet Digit Health; 2021 Aug; 3(8):e517-e525. PubMed ID: 34238721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demographic and clinical characteristics of severe Covid-19 infections: a cross-sectional study from Mashhad University of Medical Sciences, Iran.
    Goshayeshi L; Akbari Rad M; Bergquist R; Allahyari A; Hashemzadeh K; ; Hoseini B
    BMC Infect Dis; 2021 Jul; 21(1):656. PubMed ID: 34233638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paediatric, pedestrian road traffic injuries in the city of Mashhad in north-eastern Iran 2015-2019: a data note.
    Tabari P; Shabanikiya H; Bagheri N; Bergquist R; Hashtarkhani S; Kiani F; Mohammadi A; Kiani B
    BMC Res Notes; 2020 Jul; 13(1):363. PubMed ID: 32736649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
    Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
    Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lost productivity cost of absenteeism due to COVID-19 in health care workers in Iran: a case study in the hospitals of Mashhad University of Medical Sciences.
    Faramarzi A; Javan-Noughabi J; Tabatabaee SS; Najafpoor AA; Rezapour A
    BMC Health Serv Res; 2021 Oct; 21(1):1169. PubMed ID: 34711242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.